Editas Medicine, Inc. (EDIT)

Trade EDIT now with
7/7/2020 9:10:47 AM Editas Medicine, Azzur Group Announce Multi-year Agreement For EDIT-301, EDIT-201 Manufacturing
7/7/2020 9:05:55 AM Editas Medicine, Azzur Group Enter Multi-year Agreement For EDIT-301 And EDIT-201 Manufacturing
6/24/2020 12:13:17 AM Editas Medicine Reports Pricing Of Offering Of 6 Mln Common Shares At $31.25/Shr
6/15/2019 12:49:16 PM Editas Medicine Announces Results From Follow-up Study To Assess Two Different CRISPR Genome Editing Strategies
4/3/2019 7:15:07 AM Editas Medicine, BlueRock Therapeutics Enter Deal To Combine Genome Editing And Cell Therapy Platforms
1/22/2019 9:08:21 AM Editas Medicine: Katrine Bosley To Step Down From Her Role As President And CEO
12/21/2018 9:09:10 AM Editas Medicine CFO Andrew Hack To Step Down Effective March 1, 2019
12/2/2018 7:35:50 PM Editas Announces Pre-Clinical Data Supporting Novel Approach For Treatment Of Sickle Cell Disease And Beta-Thalassemia
11/30/2018 7:32:13 AM Editas Medicine Announces FDA Acceptance Of IND Application For EDIT-101
10/1/2018 9:11:26 AM Editas Medicine Names Richard Morgan SVP Of Immunogenetics
8/27/2018 4:03:31 PM Editas Medicine Says Gerald Cox To Step Down As Chief Medical Officer At Year-end
8/6/2018 4:02:20 PM Allergan, Editas Medicine Announce Exercise Of Options To Jointly Develop EDIT-101
3/14/2018 7:07:43 AM Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment Of $50 Mln